Breaking News Instant updates and real-time market news.

2020-05-28 08:15:32 CLVS Clovis $6.87 / + (+0.00%) 08:15 05/28/20 05/28 08:15 05/28/20 08:15	Clovis announces updated NCCN guidelines for Rubraca tablets Clovis announced that the National Comprehensive Cancer Network, or NCCN, updated its clinical practice guidelines in Oncology for Prostate Cancer to include new recommendations for Rubraca tablets. In addition to its ovarian cancer recommendations, Rubraca is now recommended in the NCCN Guidelines for the treatment of BRCA-mutant patients with mCRPC under second-line treatment and subsequent therapy as a Category 2A recommendation. Rucaparib is a treatment option for patients with mCRPC and a pathogenic BRCA1 or BRCA2 mutation who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. If the patient is not fit for chemotherapy, rucaparib can be considered even if taxane-based therapy has not been given. The NCCN prostate cancer panel's decision to include Rubraca as a Category 2A preferred option for the treatment of patients with a BRCA mutation for second-line treatment and subsequent therapy was based on the results of the Phase 2 TRITON2 study.	29 May 04 Jun
CLVS Clovis $6.87 / + (+0.00%) 05/22/20 H.C. Wainwright Clovis price target lowered to $29 from $33 at H.C. Wainwright 05/18/20 H.C. Wainwright Clovis price target raised to $33 from $29 at H.C. Wainwright 05/06/20 H.C. Wainwright Clovis price target raised to $29 from $27 at H.C. Wainwright 05/06/20 Piper Sandler Clovis price target raised to $6 from $5.25 at Piper Sandler

2020-05-28 08:15:32

CLVS

Clovis

$6.87 / + (+0.00%)

08:15

05/28/20

05/28

08:15

05/28/20

08:15

Clovis announces updated NCCN guidelines for Rubraca tablets

Clovis announced that the National Comprehensive Cancer Network, or NCCN, updated its clinical practice guidelines in Oncology for Prostate Cancer to include new recommendations for Rubraca tablets. In addition to its ovarian cancer recommendations, Rubraca is now recommended in the NCCN Guidelines for the treatment of BRCA-mutant patients with mCRPC under second-line treatment and subsequent therapy as a Category 2A recommendation. Rucaparib is a treatment option for patients with mCRPC and a pathogenic BRCA1 or BRCA2 mutation who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. If the patient is not fit for chemotherapy, rucaparib can be considered even if taxane-based therapy has not been given. The NCCN prostate cancer panel's decision to include Rubraca as a Category 2A preferred option for the treatment of patients with a BRCA mutation for second-line treatment and subsequent therapy was based on the results of the Phase 2 TRITON2 study.

29
May
04
Jun

CLVS Clovis

$6.87 / + (+0.00%)

05/22/20 H.C. Wainwright: Clovis price target lowered to $29 from $33 at H.C. Wainwright

05/18/20 H.C. Wainwright: Clovis price target raised to $33 from $29 at H.C. Wainwright

05/06/20 H.C. Wainwright: Clovis price target raised to $29 from $27 at H.C. Wainwright

05/06/20 Piper Sandler: Clovis price target raised to $6 from $5.25 at Piper Sandler

TODAY'S FREE FLY STORIES

Technical Analysis	NYSE market internals summary » 14:16 01/20/21 01/20 14:16 01/20/21 14:16 $NYE NYSE Market Internals $0.00 / + (+0.00%) Volume is above average… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Technical Analysis $NYE NYSE Market Internals $0.00 / + (+0.00%) 13:16 Today NYSE market internals summary 12:16 Today NYSE market internals summary 01/19/21 NYSE market internals summary 01/19/21 NYSE market internals summary
Options	Zscaler call volume above normal and directionally bullish » 14:05 01/20/21 01/20 14:05 01/20/21 14:05 ZS Zscaler $215.81 / +3.81 (+1.80%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options ZS Zscaler $215.81 / +3.81 (+1.80%) 12/23/20 Zscaler launches security assessment program following SolarWinds attack 11/12/20 Zscaler appoints Chris Kozup as CMO 09/30/20 Zscaler director sells 20K shares of common stock 09/29/20 JFrog appoints Micheline Nijmeh as chief marketing officer ZS Zscaler $215.81 / +3.81 (+1.80%) 09:56 Today Fly Intel: Top five analyst initiations 06:07 Today JMP Securities Zscaler initiated with an Outperform at JMP Securities 01/12/21 Needham Zscaler price target raised to $240 from $215 at Needham 01/12/21 Credit Suisse Zscaler price target raised to $215 from $175 at Credit Suisse ZS Zscaler $215.81 / +3.81 (+1.80%) 12/03/20 Zscaler raises FY21 EPS view to 37c-38c from 28c-30c, consensus 31c 12/02/20 Zscaler sees Q2 EPS 7c-8c, consensus 7c 12/02/20 Zscaler reports Q1 EPS 14c, consensus 6c 12/02/20 Notable companies reporting after market close ZS Zscaler $215.81 / +3.81 (+1.80%) 09/01/20 Hackers test security of Trump campaign sites ahead of election, Reuters says ZS Zscaler $215.81 / +3.81 (+1.80%) 12/23/20 Qualcomm initiation, IAC downgrade among today's top calls on Wall Street 12/21/20 Analysts move to sidelines on SolarWinds following cyberattack 12/03/20 Fly Intel: Wall Street's top stories for Thursday 12/03/20 Fly Intel: Wall Street's top stories at midday ZS Zscaler $215.81 / +3.81 (+1.80%) 12/07/20 Zscaler put volume heavy and directionally bearish 12/04/20 Unusually active option classes on open December 4th 12/02/20 Zscaler options imply 13.7% move in share price post-earnings 09/17/20 Zscaler put volume heavy and directionally bearish
Recommendations	Exelixis selloff on competitive concerns an 'overreaction,' says William Blair » 14:04 01/20/21 01/20 14:04 01/20/21 14:04 EXEL Exelixis $21.75 / -1.86 (-7.88%) , BMY Bristol-Myers $66.15 / -0.59 (-0.88%) , MRK Merck $82.52 / -0.66 (-0.79%) , ESALY Eisai $0.00 / + (+0.00%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options EXEL BMY MRK ESALY EXEL Exelixis $21.75 / -1.86 (-7.88%) 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact BMY Bristol-Myers $66.15 / -0.59 (-0.88%) 07:01 Today Bristol-Myers: FDA accepts for Priority Review sBLA for Opdivo combination 01/11/21 Bristol-Myers CEO: Our strategy for growth is based on innovation 01/11/21 Illumina announces new and expanded oncology partnerships 01/11/21 Bristol-Myers announces $2B incremental share repurchase plan MRK Merck $82.52 / -0.66 (-0.79%) 06:49 Today Merck granted FDA approval of Verquvo for cardiosvacular risk reduction 01/19/21 Cocrystal Pharma completes research obligations under Merck agreement 01/19/21 Atea Pharmaceuticals appoints Jayanthi Wolf as SVP, regulatory affairs 01/14/21 Philips. Merck partner on personalized fertility treatment solutions ESALY Eisai $0.00 / + (+0.00%) 12/16/20 Merck, Eisai: KEYTRUDA plus LENVIMA showed significant improvement in OS 12/10/20 Biogen submits aducanumab J-NDA to Ministry of Health, Labor and Welfare 11/10/20 Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint 11/09/20 Eisai presents latest BAN2401 data at CTAD EXEL BMY MRK ESALY EXEL Exelixis $21.75 / -1.86 (-7.88%) 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler BMY Bristol-Myers $66.15 / -0.59 (-0.88%) 06:51 Today Citi Citi opens 'negative Catalyst Watch' on Bristol-Myers 12/15/20 Goldman Sachs Bristol-Myers upgraded to Conviction Buy from Buy at Goldman Sachs 12/09/20 Mizuho Pentwater seeks to replace Bristol-Myers Squibb CVR trustee, says Mizuho 11/30/20 Citi Bristol-Myers price target raised to $77 from $73 at Citi MRK Merck $82.52 / -0.66 (-0.79%) 06:51 Today Citi Citi opens 'negative Catalyst Watch' on Bristol-Myers 01/06/21 Citi Citi opens 'positive catalyst watch' on Merck 01/05/21 Citi Citi boosts Merck target to $105, says may be most undervalued in pharma 12/22/20 Mizuho Autolus, Arcus among top 2021 oncology picks at Mizuho ESALY Eisai $0.00 / + (+0.00%) 11/05/20 Jefferies Eisai upgraded to Buy from Hold at Jefferies 09/08/20 Jefferies Eisai downgraded to Hold from Buy at Jefferies EXEL BMY MRK EXEL Exelixis $21.75 / -1.86 (-7.88%) 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c BMY Bristol-Myers $66.15 / -0.59 (-0.88%) 11/05/20 Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39 11/05/20 Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25 11/05/20 Bristol-Myers reports Q3 EPS $1.63, consensus $1.49 11/04/20 Notable companies reporting before tomorrow's open MRK Merck $82.52 / -0.66 (-0.79%) 10/27/20 Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78 10/27/20 Merck reports Q3 adjusted EPS $1.74, consensus $1.43 10/26/20 Notable companies reporting before tomorrow's open 10/26/20 Notable companies reporting before tomorrow's open BMY MRK BMY Bristol-Myers $66.15 / -0.59 (-0.88%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 10/05/20 Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports MRK Merck $82.52 / -0.66 (-0.79%) 12/23/20 Judge rules against White House drug pricing rule, Reuters says 12/19/20 Alphabet, Apple among Barron's 10 Top stocks for 2021, Barron's says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports BMY MRK ESALY BMY Bristol-Myers $66.15 / -0.59 (-0.88%) 12/26/20 Week in review: How Trump's policies moved stocks 11/21/20 Week in review: How Trump's policies moved stocks 11/05/20 Fly Intel: Pre-market Movers 10/08/20 Cytokinetics plunges following mixed results from heart drug trial MRK Merck $82.52 / -0.66 (-0.79%) 12/26/20 Week in review: How Trump's policies moved stocks 12/02/20 Fly Intel: Wall Street's top stories at midday 12/02/20 Fly Intel: Pre-market Movers 11/23/20 Fly Intel: Wall Street's top stories for Monday ESALY Eisai $0.00 / + (+0.00%) 08/07/20 Fly Intel: Wall Street's top stories at midday 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 02/04/21 Merck - MRK 02/04/21 Bristol-Myers - BMY 00:00 Today PDUFA Date for Vericiguat 02/09/21 Oncologic Drugs Advisory Committee Virtual Meeting 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 03/27/21 PDUFA Date for Ide-Cel 04/13/21 PDUFA Date for Keytrude w/Chemotherapy 07/18/21 PDUFA Date for V114 BMY MRK BMY Bristol-Myers $66.15 / -0.59 (-0.88%) 09:40 Today Unusually active option classes on open January 20th 01/11/21 Unusually active option classes on open January 11th 01/05/21 Bristol Myers Squibb call volume above normal and directionally bullish 01/04/21 Bristol Myers Squibb call buyer realizes 25% same-day gains MRK Merck $82.52 / -0.66 (-0.79%) 12/23/20 Merck call volume above normal and directionally bullish 10/20/20 Merck put volume heavy and directionally bearish 08/06/20 Unusually active option classes on open August 6th 08/05/20 Merck call volume above normal and directionally bullish
Hot Stocks	North American rail traffic rose 8.6% in the week ended January 16 » 14:02 01/20/21 01/20 14:02 01/20/21 14:02 CNI Canadian National $110.15 / +0.4 (+0.36%) , CP Canadian Pacific $352.75 / +1.52 (+0.43%) , CSX CSX $93.17 / +0.49 (+0.53%) , KSU Kansas City Southern $215.74 / +4.045 (+1.91%) , NSC Norfolk Southern $252.54 / +2.74 (+1.10%) , UNP Union Pacific $218.00 / +2.76 (+1.28%) , GWR Genesee & Wyoming $111.91 / + (+0.00%) The Association of… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CNI CP CSX KSU NSC UNP GWR CNI Canadian National $110.15 / +0.4 (+0.36%) 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 12/31/20 North American rail traffic rose 7% in week ended December 26 12/30/20 CN completes U.S. federal requirement to operate Positive Train Control CP Canadian Pacific $352.75 / +1.52 (+0.43%) 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 12/31/20 North American rail traffic rose 7% in week ended December 26 12/24/20 North American rail traffic rose 1.9% in week ended December 19 CSX CSX $93.17 / +0.49 (+0.53%) 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 12/31/20 North American rail traffic rose 7% in week ended December 26 12/24/20 North American rail traffic rose 1.9% in week ended December 19 KSU Kansas City Southern $215.74 / +4.045 (+1.91%) 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 12/31/20 North American rail traffic rose 7% in week ended December 26 12/24/20 North American rail traffic rose 1.9% in week ended December 19 NSC Norfolk Southern $252.54 / +2.74 (+1.10%) 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 12/31/20 North American rail traffic rose 7% in week ended December 26 12/24/20 North American rail traffic rose 1.9% in week ended December 19 UNP Union Pacific $218.00 / +2.76 (+1.28%) 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/10/21 Fly Intel: Top five weekend stock stories 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 12/31/20 North American rail traffic rose 7% in week ended December 26 GWR Genesee & Wyoming $111.91 / + (+0.00%) 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 12/31/20 North American rail traffic rose 7% in week ended December 26 12/24/20 North American rail traffic rose 1.9% in week ended December 19 CNI CP CSX KSU NSC UNP GWR CNI Canadian National $110.15 / +0.4 (+0.36%) 09:01 Today Scotiabank Canadian National downgraded to Sector Perform from Outperform at Scotiabank 01/13/21 Barclays Canadian National upgraded to Equal Weight from Underweight at Barclays 01/11/21 Bernstein Canadian National upgraded to Outperform from Market Perform at Bernstein 01/11/21 Citi Canadian National price target raised to $127 from $110 at Citi CP Canadian Pacific $352.75 / +1.52 (+0.43%) 09:01 Today Scotiabank Canadian Pacific downgraded to Sector Perform from Outperform at Scotiabank 01/19/21 CIBC Canadian Pacific price target raised to C$500 from C$490 at CIBC 01/11/21 Citi Canadian Pacific price target raised to $430 from $355 at Citi 12/17/20 National Bank Canadian Pacific price target raised to C$445 from C$433 at National Bank CSX CSX $93.17 / +0.49 (+0.53%) 07:18 Today Susquehanna Railroad recovery expected to continue in 2021, says Susquehanna 01/11/21 Citi CSX price target raised to $105 from $87 at Citi 12/10/20 Morgan Stanley Morgan Stanley downgrades CSX to Underweight with bar raised too high 12/10/20 Morgan Stanley CSX downgraded to Underweight from Equal Weight at Morgan Stanley KSU Kansas City Southern $215.74 / +4.045 (+1.91%) 01/15/21 Raymond James Kansas City Southern price target raised to $245 from $210 at Raymond James 01/12/21 JPMorgan Kansas City Southern price target raised to $204 from $199 at JPMorgan 01/11/21 Citi Kansas City Southern price target raised to $250 from $220 at Citi 12/10/20 Morgan Stanley Morgan Stanley downgrades CSX to Underweight with bar raised too high NSC Norfolk Southern $252.54 / +2.74 (+1.10%) 07:18 Today Susquehanna Railroad recovery expected to continue in 2021, says Susquehanna 01/13/21 Baird Norfolk Southern upgraded to Outperform with $286 price target at Baird 01/12/21 Baird Norfolk Southern upgraded to Outperform from Neutral at Baird 01/11/21 Citi Norfolk Southern price target raised to $290 from $250 at Citi UNP Union Pacific $218.00 / +2.76 (+1.28%) 07:18 Today Susquehanna Railroad recovery expected to continue in 2021, says Susquehanna 01/15/21 Raymond James Union Pacific price target raised to $250 from $220 at Raymond James 01/12/21 JPMorgan Union Pacific price target raised to $216 from $212 at JPMorgan 01/11/21 Bernstein Union Pacific upgraded to Outperform from Market Perform at Bernstein GWR Genesee & Wyoming $111.91 / + (+0.00%) CNI CP CSX KSU NSC UNP CNI Canadian National $110.15 / +0.4 (+0.36%) 10/20/20 Canadian National reports Q3 EPS $C$1.38 versus $C1.66 in Q319 07/21/20 Canadian National reports Q2 EPS C$1.28, consensus C$1.26 CP Canadian Pacific $352.75 / +1.52 (+0.43%) 10/20/20 Canadian Pacific sees at least mid-single-digit adjusted EPS growth in 2020 10/20/20 Canadian Pacific reports Q3 adjusted EPS C$4.12 vs. C$4.61 last year 07/22/20 Canadian Pacific sees adjusted diluted EPS growth year over year 07/22/20 Canadian Pacific reports Q2 adjusted EPS C$4.07 vs. C$4.30 last year CSX CSX $93.17 / +0.49 (+0.53%) 10/21/20 CSX reports Q3 EPS 96c, consensus 92c 10/21/20 Notable companies reporting after market close 07/22/20 CSX reports Q2 EPS 65c, consensus 64c 07/22/20 Notable companies reporting after market close KSU Kansas City Southern $215.74 / +4.045 (+1.91%) 12/03/20 Kansas City Southern says Q4 revenue-to-date down 5% 10/16/20 Kansas City Southern reports Q3 adj. EPS $1.96, consensus $1.90 10/15/20 Notable companies reporting before tomorrow's open 10/15/20 Notable companies reporting before tomorrow's open NSC Norfolk Southern $252.54 / +2.74 (+1.10%) 10/28/20 Norfolk Southern reports Q3 adjusted EPS $2.51, consensus $2.38 10/27/20 Notable companies reporting before tomorrow's open 10/27/20 Notable companies reporting before tomorrow's open 10/09/20 Norfolk Southern sees Q3 railway operating revenues of about $2.5B UNP Union Pacific $218.00 / +2.76 (+1.28%) 10/22/20 Union Pacific reports Q3 EPS $2.01, consensus $2.05 10/21/20 Notable companies reporting before tomorrow's open 10/21/20 Notable companies reporting before tomorrow's open 07/23/20 Union Pacific reports Q2 EPS $1.67, consensus $1.55 KSU NSC UNP KSU Kansas City Southern $215.74 / +4.045 (+1.91%) 11/10/20 Kansas City Southern potential bidders have moved on, CNBC reports 09/09/20 Kansas City Southern rejects $20B buyout bid from PE suitors, WSJ says 09/09/20 Kansas City Southern rejects $20B buyout bid from PE suitors, WSJ says 09/02/20 Blackstone, GIP make bid to buy Kansas City Southern, WSJ says NSC Norfolk Southern $252.54 / +2.74 (+1.10%) 11/13/20 Norfolk Southern, ViacomCBS highlighted by Dealreporter amid 'interesting' 13Fs UNP Union Pacific $218.00 / +2.76 (+1.28%) 01/09/21 Some century-old stocks still deliver, Barron's says 08/14/20 Union Pacific issues second spot rate increase in California, JOC.com reports CSX KSU UNP CSX CSX $93.17 / +0.49 (+0.53%) 10/21/20 Fly Intel: After-Hours Movers KSU Kansas City Southern $215.74 / +4.045 (+1.91%) 09/10/20 Fly Intel: Wall Street's top stories for Thursday 09/10/20 Fly Intel: Wall Street's top stories at midday 09/09/20 Fly Intel: After-Hours Movers 09/02/20 Fly Intel: Wall Street's top stories for Wednesday UNP Union Pacific $218.00 / +2.76 (+1.28%) 10/22/20 Fly Intel: Pre-market Movers 02/09/21 42nd Annual Aerospace/Defense & Industrials Virtual Conference 01/21/21 Union Pacific - UNP 01/21/21 CSX - CSX 01/22/21 Kansas City Southern - KSU 01/26/21 Canadian National - CNI 01/27/21 Norfolk Southern - NSC 01/27/21 Canadian Pacific - CP CSX KSU NSC UNP CSX CSX $93.17 / +0.49 (+0.53%) 10/22/20 Early notable gainers among liquid option names on October 22nd 09/15/20 CSX call volume above normal and directionally bullish 09/04/20 CSX put volume heavy and directionally bearish 07/31/20 CSX call volume above normal and directionally bullish KSU Kansas City Southern $215.74 / +4.045 (+1.91%) 07/31/20 Kansas City Southern bid could be valued over $21B with debt, WSJ reports NSC Norfolk Southern $252.54 / +2.74 (+1.10%) 08/27/20 Unusually active option classes on open August 27th UNP Union Pacific $218.00 / +2.76 (+1.28%) 11/10/20 Union Pacific put volume heavy and directionally bearish 08/03/20 Union Pacific put volume heavy and directionally bearish
General news	Wall Street has rallied into fresh record high territory » 14:00 01/20/21 01/20 14:00 01/20/21 14:00 Wall Street has rallied… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

Recommendations	Flughafen Zuerich price target raised to CHF 166 from CHF 157 at Barclays » 13:59 01/20/21 01/20 13:59 01/20/21 13:59 FLGZY Flughafen Zuerich $0.00 / + (+0.00%) Barclays analyst Rishika… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research FLGZY Flughafen Zuerich $0.00 / + (+0.00%) 12/17/20 Morgan Stanley Flughafen Zuerich price target raised to CHF 169 from CHF 164 at Morgan Stanley 12/04/20 Deutsche Bank Flughafen Zuerich price target raised to CHF 182 from CHF 157 at Deutsche Bank 11/30/20 UBS Flughafen Zuerich downgraded to Neutral from Buy at UBS 11/25/20 Morgan Stanley Flughafen Zuerich price target raised to CHF 164 from CHF 137 at Morgan Stanley
Recommendations	Wizz Air price target raised to 4,880 GBp from 3,785 GBp at Barclays » 13:57 01/20/21 01/20 13:57 01/20/21 13:57 WZZAF Wizz Air $0.00 / + (+0.00%) Barclays analyst Rishika… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research WZZAF Wizz Air $0.00 / + (+0.00%) 12:03 Today JPMorgan Wizz Air price target lowered to 5,725 GBp from 5,850 GBp at JPMorgan 12/07/20 HSBC Wizz Air downgraded to Hold from Buy at HSBC 12/07/20 HSBC Wizz Air downgraded to Hold from Buy at HSBC 12/04/20 Deutsche Bank Wizz Air price target raised to 5,200 GBp from 5,000 GBp at Deutsche Bank
Recommendations	Telefonica Deutschland price target lowered to EUR 3 from EUR 3.10 at Barclays » 13:56 01/20/21 01/20 13:56 01/20/21 13:56 TELDF Telefonica Deutschland $0.00 / + (+0.00%) Barclays analyst Mathieu… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research TELDF Telefonica Deutschland $0.00 / + (+0.00%) 11/03/20 Morgan Stanley Telefonica Deutschland price target raised to EUR 3.10 at Morgan Stanley 11/03/20 MainFirst Telefonica Deutschland upgraded to Buy from Hold at MainFirst 11/02/20 UBS Telefonica Deutschland price target lowered to EUR 3.20 from EUR 3.40 at UBS 10/20/20 Morgan Stanley Telefonica Deutschland price target lowered to EUR 3 at Morgan Stanley
Hot Stocks	Tutor Perini unit announces two federal contracts collectively valued at $66.9M » 13:55 01/20/21 01/20 13:55 01/20/21 13:55 TPC Tutor Perini $16.71 / -0.33 (-1.94%) Tutor Perini Corporation… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings TPC Tutor Perini $16.71 / -0.33 (-1.94%) 11/09/20 Tutor Perini awarded $54M contract to complete project in Los Angeles 09/30/20 Tutor Perini receives partial arbitration award of $23.6M against Gary Segal 09/22/20 Tutor Perini awarded $47M task order 09/18/20 Tutor Perini CEO sells 40,000 common shares TPC Tutor Perini $16.71 / -0.33 (-1.94%) 01/07/21 B. Riley Securities Tutor Perini price target raised to $22 from $19 at B. Riley Securities 07/30/20 B. Riley FBR Tutor Perini price target raised to $20 from $18 at B. Riley FBR 02/28/20 DA Davidson DA Davidson skeptical Tutor Perini CEO would look to sell 02/27/20 DA Davidson Tutor Perini price target lowered to $18 from $22 at DA Davidson TPC Tutor Perini $16.71 / -0.33 (-1.94%) 11/04/20 Tutor Perini backs FY20 EPS view $1.80-$2.10, consensus $1.99 11/04/20 Tutor Perini reports Q3 EPS 72c, consensus 65c 07/29/20 Tutor Perini backs FY20 EPS view $1.80-$2.10, consensus $2.00 07/29/20 Tutor Perini reports Q2 EPS 37c, consensus 41c
Recommendations	Ryanair price target raised to EUR 17.30 from EUR 14.50 at Barclays » 13:54 01/20/21 01/20 13:54 01/20/21 13:54 RYAAY Ryanair $106.82 / +0.61 (+0.57%) Barclays analyst Rishika… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals RYAAY Ryanair $106.82 / +0.61 (+0.57%) 12/27/20 Fly Intel: Top five weekend stock stories 12/03/20 Boeing confirms order for 75 additional 737 MAX airplanes from Ryanair 12/03/20 Ryanair hopes to take delivery of at least 50 MAX aircraft in 2021 12/03/20 Ryanair says Max order helps return to growth across Europe in 2021 RYAAY Ryanair $106.82 / +0.61 (+0.57%) 06:57 Today JPMorgan Ryanair downgraded to Neutral from Overweight at JPMorgan 12/17/20 Morgan Stanley Ryanair price target raised to EUR 18 from EUR 15.60 at Morgan Stanley 12/16/20 Raymond James Ryanair price target raised to $125 from $100 at Raymond James 12/07/20 UBS Ryanair price target raised to EUR 15.65 from EUR 14.70 at UBS RYAAY Ryanair $106.82 / +0.61 (+0.57%) 12/26/20 Delta, Southwest among airline stocks that could cruise higher, Barron's says 12/22/20 Germany extends U.K. travel ban to January 6, Sky News reports 12/07/20 IAG dismisses Ryanair comments on British Airways holding, Reuters says 12/02/20 Ryanair close to placing order for Boeing 737 MAX jets, Reuters reports

Recommendations	Marks & Spencer price target raised to 165 GBp from 140 GBp at Barclays » 13:53 01/20/21 01/20 13:53 01/20/21 13:53 MAKSY Marks & Spencer $0.00 / + (+0.00%) Barclays analyst James… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research MAKSY Marks & Spencer $0.00 / + (+0.00%) 01/12/21 Citi Marks & Spencer price target raised to 155 GBp from 120 GBp at Citi 11/26/20 Goldman Sachs Marks & Spencer downgraded to Neutral from Buy at Goldman Sachs 11/20/20 Redburn Marks & Spencer upgraded to Neutral from Sell at Redburn 11/20/20 Redburn Marks & Spencer upgraded to Neutral from Sell at Redburn
Recommendations	LafargeHolcim price target raised to CHF 57 from CHF 54 at Barclays » 13:53 01/20/21 01/20 13:53 01/20/21 13:53 HCMLY LafargeHolcim $0.00 / + (+0.00%) Barclays analyst Nabil… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Periodicals HCMLY LafargeHolcim $0.00 / + (+0.00%) 11:39 Today UBS LafargeHolcim price target raised to CHF 57 from CHF 48 at UBS 01/14/21 Berenberg LafargeHolcim initiated with a Hold at Berenberg 01/08/21 JPMorgan LafargeHolcim price target raised to CHF 59 from CHF 51 at JPMorgan 12/07/20 Jefferies LafargeHolcim initiated with a Hold at Jefferies HCMLY LafargeHolcim $0.00 / + (+0.00%) 01/04/21 LafargeHolcim in talks to acquire Bridgestone unit, Bloomberg says
Recommendations	IAG price target raised to 175 GBp from 120 GBp at Barclays » 13:52 01/20/21 01/20 13:52 01/20/21 13:52 ICAGY IAG $0.00 / + (+0.00%) Barclays analyst Rishika… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals ICAGY IAG $0.00 / + (+0.00%) 07/24/20 IAG 'evaluating the merits of a rights issue' of up to EUR 2.75B ICAGY IAG $0.00 / + (+0.00%) 12/31/20 Fly Intel: Top five analyst calls 12/31/20 Citi IAG upgraded to Buy from Neutral at Citi 12/04/20 Deutsche Bank IAG price target raised to 220 GBp from 175 GBp at Deutsche Bank 12/01/20 UBS IAG price target raised to 225 GBp from 190 GBp at UBS ICAGY IAG $0.00 / + (+0.00%) 12/07/20 IAG dismisses Ryanair comments on British Airways holding, Reuters says 11/05/20 British Airways to reduce flight schedule in November, Reuters reports
Recommendations	HeidelbergCement price target raised to EUR 74 from EUR 64 at Barclays » 13:51 01/20/21 01/20 13:51 01/20/21 13:51 HDELY HeidelbergCement $0.00 / + (+0.00%) Barclays analyst Nabil… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research HDELY HeidelbergCement $0.00 / + (+0.00%) 11:38 Today UBS HeidelbergCement price target raised to EUR 71.50 from EUR 68.50 at UBS 01/14/21 Berenberg HeidelbergCement initiated with a Buy at Berenberg 01/08/21 JPMorgan HeidelbergCement price target raised to EUR 70 from EUR 60 at JPMorgan 01/06/21 Societe Generale HeidelbergCement upgraded to Buy from Hold at Societe Generale
Recommendations	Fraport price target raised to EUR 38 from EUR 32 at Barclays » 13:50 01/20/21 01/20 13:50 01/20/21 13:50 FPRUY Fraport $0.00 / + (+0.00%) Barclays analyst Rishika… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research FPRUY Fraport $0.00 / + (+0.00%) 12/17/20 Morgan Stanley Fraport price target raised to EUR 55 from EUR 54 at Morgan Stanley 12/17/20 Nord/LB Fraport downgraded to Sell from Hold at Nord/LB 12/03/20 Deutsche Bank Fraport upgraded to Buy from Hold at Deutsche Bank 12/01/20 HSBC Fraport downgraded to Hold from Buy at HSBC

Conference/Events	Midwest Energy Emissions to host conference call » 13:46 01/20/21 01/20 13:46 01/20/21 13:46 MEEC Midwest Energy Emissions $0.00 / + (+0.00%) Management holds a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings MEEC Midwest Energy Emissions $0.00 / + (+0.00%) 01/19/21 Midwest Energy Emissions reaches license agreement with North American utility 01/11/21 Midwest Energy Emissions announces agreement with major national utility 12/01/20 Midwest Energy Emissions, AEP sign agreement for non-exclusive license 10/19/20 Midwest Energy Emissions engages MZ Group to lead investor relations MEEC Midwest Energy Emissions $0.00 / + (+0.00%) 11/24/20 Midwest Energy Emissions reports Q3 EPS (1c) vs. (1c) last year
Options	Clovis call volume above normal and directionally bullish » 13:45 01/20/21 01/20 13:45 01/20/21 13:45 CLVS Clovis $6.57 / +0.44 (+7.18%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options CLVS Clovis $6.57 / +0.44 (+7.18%) 01/11/21 Clovis sees Q4 Rubraca global product revenues of $43M-$43.5M 12/29/20 Clovis completes submission of two new IND apps to FDA for FAP-2286 12/21/20 Clovis announces Rubraca met primary endpoint of InvPFS compared to chemotherapy 09/17/20 Clovis to present data from oncology program at ESMO CLVS Clovis $6.57 / +0.44 (+7.18%) 01/11/21 Piper Sandler Piper Sandler keeps Neutral on Clovis despite 'encouraging' Rubraca quarter 11/06/20 H.C. Wainwright Clovis price target lowered to $15 from $23 at H.C. Wainwright 11/05/20 Piper Sandler Clovis price target lowered to $5 from $6 at Piper Sandler 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology CLVS Clovis $6.57 / +0.44 (+7.18%) 11/05/20 Clovis sees Q4 revenue $38M-$40M, consensus $46.93M 11/05/20 Clovis reports Q3 EPS (89c), consensus (99c) 08/06/20 Clovis reports Q2 EPS ($1.15), consensus ($1.04) 19 May CLVS Clovis $6.57 / +0.44 (+7.18%) 11/05/20 Fly Intel: Wall Street's top stories for Thursday 11/05/20 Fly Intel: Wall Street's top stories at midday 08/27/20 Fly Intel: Pre-market Movers 08/06/20 Fly Intel: After-Hours Movers 02/23/21 Clovis - CLVS CLVS Clovis $6.57 / +0.44 (+7.18%) 12/23/20 Largest borrow rate increases among liquid names 12/14/20 Clovis call volume above normal and directionally bullish 12/03/20 Clovis call volume above normal and directionally bullish 11/10/20 Largest borrow rate increases among liquid names
Hot Stocks	Tuscan Holdings Corporation II (Units) trading resumes 13:44 01/20/21 01/20 13:44 01/20/21 13:44
Conference/Events	JPMorgan airfreight analysts to hold an analyst/industry conference call » 13:43 01/20/21 01/20 13:43 01/20/21 13:43 Global Airfreight… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Recommendations	easyJet price target raised to 850 GBp from 630 GBp at Barclays » 13:42 01/20/21 01/20 13:42 01/20/21 13:42 ESYJY easyJet $0.00 / + (+0.00%) Barclays analyst Rishika… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Periodicals ESYJY easyJet $0.00 / + (+0.00%) 12:05 Today Citi easyJet price target lowered to 600 GBp at Citi 12:00 Today JPMorgan easyJet price target lowered to 825 GBp from 875 GBp at JPMorgan 11:29 Today Credit Suisse easyJet price target raised to 934 GBp from 840 GBp at Credit Suisse 12/31/20 Fly Intel: Top five analyst calls ESYJY easyJet $0.00 / + (+0.00%) 12/22/20 Germany extends U.K. travel ban to January 6, Sky News reports

Conference/Events	BTIG medical technology analyst to hold analyst/industry conference call » 13:42 01/20/21 01/20 13:42 01/20/21 13:42 Medical Technology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Recommendations	Diageo price target raised to 3,570 GBp from 3,040 GBp at Barclays » 13:42 01/20/21 01/20 13:42 01/20/21 13:42 DEO Diageo $159.83 / -0.02 (-0.01%) Barclays analyst Laurence… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals DEO Diageo $159.83 / -0.02 (-0.01%) 08/17/20 Diageo to acquire Aviation Gin, Davos brand for up to $610M DEO Diageo $159.83 / -0.02 (-0.01%) 01/15/21 Berenberg Diageo price target raised to 3,080 GBp from 2,810 GBp at Berenberg 01/15/21 Deutsche Bank Diageo price target lowered to 3,850 GBp from 3,900 GBp at Deutsche Bank 12/03/20 JPMorgan Diageo price target raised to 2,700 GBp from 2,475 GBp at JPMorgan 12/01/20 Deutsche Bank Diageo upgraded to Buy from Hold at Deutsche Bank DEO Diageo $159.83 / -0.02 (-0.01%) 09/28/20 Diageo says outlook for first half of fiscal 21 has improved since year-end DEO Diageo $159.83 / -0.02 (-0.01%) 11/23/20 Diageo CEO says 'on the hunt' to buy more premium brands, CNBC reports 08/10/20 Carlyle weighs exit from $1.2B packaging company Logoplaste, Bloomberg says
Recommendations	Lufthansa price target raised to EUR 6.10 from EUR 5.10 at Barclays » 13:40 01/20/21 01/20 13:40 01/20/21 13:40 DLAKY Lufthansa $0.00 / + (+0.00%) Barclays analyst Rishika… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Periodicals DLAKY Lufthansa $0.00 / + (+0.00%) 12/04/20 Deutsche Bank Lufthansa price target raised to EUR 7 from EUR 5.20 at Deutsche Bank 12/01/20 UBS Lufthansa price target lowered to EUR 5 from EUR 5.30 at UBS 11/12/20 Kepler Cheuvreux Lufthansa upgraded to Buy from Reduce at Kepler Cheuvreux 11/10/20 Goldman Sachs Lufthansa upgraded to Neutral from Sell at Goldman Sachs DLAKY Lufthansa $0.00 / + (+0.00%) 10/20/20 Lufthansa sees Q3 adj. EBIT loss EUR1.26B vs. profit EUR1.30B last year DLAKY Lufthansa $0.00 / + (+0.00%) 12/22/20 Germany extends U.K. travel ban to January 6, Sky News reports 10/05/20 Lufthansa CEO says airline far from breaking even, Reuters reports
Conference/Events	Truist leisure/lodging analysts hold an analyst/industry conference call » 13:39 01/20/21 01/20 13:39 01/20/21 13:39 Lodging Analysts discuss… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Conference/Events	Stephens specialty finance analyst to hold analyst/industry conference call » 13:38 01/20/21 01/20 13:38 01/20/21 13:38 Specialty Finance Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

Events

Earnings calls, analyst events, roadshows and more

KMI
Today at 16:30

Kinder Morgan - KMI Conference Calls
AA
Today at 17:00

Alcoa - AA Conference Calls
HWC
Today at 17:00

Hancock Whitney - HWC Conference Calls
NVEC
Today at 17:00

NVE Corp. - NVEC Conference Calls
Tomorrow at 00:00

Oncology Investor Virtual Conference Conferences

Virtual Conference
Tomorrow at 00:00

Western Institutional Investor Virtual Conference Conferences

Virtual Conference
Tomorrow at 00:00

China Automotive & Industrialo Access Days Virtual Conference Conferences

Virtual Conference
AGN ...
Tomorrow at 00:00

Aesthetics Tech Virtual Summit 2021 Conferences

Virtual Summit
Tomorrow at 00:00

2021 VESS Annual Winter Meeting Conferences

Virtual Meeting
CLAR ...
Tomorrow at 00:00

Virtual Outdoor Day Conferences

Virtual Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	BDGE X BDGE Bridge Bancorp Block Trade Managers: Morgan Stanley Priced at: $25.50 700K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TCRR X TCRR TCR2 Therapeutics Secondary Managers: Goldman Sachs, Jefferies, Piper Sandler & BMO Capital Priced at: $30.50 4.59M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRS X ACRS Aclaris Therapeutics Spot Secondary Managers: Cantor Fitzgerald & William Blair, H.C. Wainwright Priced at: $17.50 5.484M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ACRX X ACRX AcelRx Spot Secondary Managers: Cantor Fitzgerald Priced at: $1.90 14.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BLRX X BLRX BioLineRx Spot Secondary Managers: H.C. Wainwright Priced at: $2.40 12.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNGO X BNGO Bionano Genomics Spot Secondary Managers: Oppenheimer, BTIG, Ladenburg, Maxim Priced at: $6.00 33.333M Shares DSS X DSS Document Security Spot Secondary Managers: Aegis Priced at: $3.60 6.67M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: SVB Leerink, Piper Sandler & Credit Suisse Priced at: $11.00 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LAC X LAC Lithium Americas Spot Secondary Managers: Canaccord, Deutsche Bank, Evercore ISI, Stifel Priced at: $22.00 15.9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PERI X PERI Perion Network Spot Secondary Managers: Oppenheimer, Stifel, Roth Capital, LAKE Priced at: $11.50 4.99M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYRS X SYRS Syros Pharmaceuticals Spot Secondary Managers: Cowen & Piper Sandler Priced at: $14.00 5.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	DFH X DFH Dream Finders Homes IPO Managers: BofA, RBC Capital & BTIG, Builder Advisor, Zelman, TCB Capital, Wedbush $12.00-15.00 9.6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MYTE X MYTE Mytheresa IPO Managers: Morgan Stanley & JPMorgan, Credit Suisse, UBS, Jefferies, Cowen $24.00-26.00 15.647M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RLX X RLX RLX Technology IPO Managers: Citi, China Renaissance $8.00-10.00 116.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ATHA X ATHA Athira Pharma Secondary Managers: Goldman Sachs, Jefferies, Stifel & JMP Securities $26.55 4M Shares CDNA X CDNA CareDx Secondary Managers: Goldman Sachs & Jefferies, Raymond James, BTIG, Craig-Hallum, H.C. Wainwright $93.33 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CMRX X CMRX Chimerix Secondary Managers: Jefferies & Cowen, H.C. Wainwright, JonesTrading $8.10 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CTMX X CTMX CytomX Therapeutics Secondary Managers: JPMorgan, Cowen & Piper Sandler $8.48 Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $76.12 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DYN X DYN Dyne Therapeutics Secondary Managers: JPMorgan, Jefferies, Piper Sandler & Stifel $28.61 5.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDIT X EDIT Editas Medicine Secondary Managers: JPMorgan & Morgan Stanley, Cowen, Credit Suisse $72.11 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MRUS X MRUS Merus Secondary Managers: Jefferies & SVB Leerink $24.71 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CYRX X CYRX Cryoport Spot Secondary Managers: Morgan Stanley, Jefferies, SVB Leerink & UBS $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	PAX X PAX Patria IPO Managers: JPMorgan, BofA & Credit Suisse, Goldman Sachs, Bradesco BBI, BTG Pactual, ITAU, Keefe Bruyette, Santander, XP $14.00-16.00 26.65M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AZEK X AZEK Azek Secondary Managers: Barclays, BofA, Goldman Sachs & Jefferies $42.25 17.5M Shares CRSR X CRSR Corsair Gaming Secondary Managers: Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen, & Stifel, Wedbush, Academy Securities $37.73 7.5M Shares PASG X PASG Passage Bio Secondary Managers: JPMorgan, Goldman Sachs & Cowen, Wedbush, Chardan $29.05 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Clovis announces updated NCCN guidelines for Rubraca tablets

TODAY'S FREE FLY STORIES

Get Full Fly Access